

Shenzhen Yibo Technology Co., Ltd.,  
E District 4F, 5 Building, Wen Ge  
Industrial Zone, Heshuikou, Gongming  
St., Guangming New District, Shenzhen  
City, Guangdong Province, China  
518106.

Twist Vapor Franchising, LLC, 14937  
Bruce B Downs Boulevard, Tampa, FL  
33613.

United Wholesale LLC, 73 Linden  
Street, Glastonbury, CT 06033.

Vape4U LLC, 8926 Benson Ave. Ste E,  
Montclair, CA 91763.

Vaperz LLC, 19818 S Harlem Ave.,  
Frankfort, IL 60423.

Vaportronix, LLC, 2941 NE 185th  
Street, Aventura, FL 33180.

Vapor 4 Life Holdings, Inc., 4080  
Commercial Ave., Suite A, Northbrook,  
IL 60062.

The ZFO, 42 Nichols St., Suite 14,  
Spencerport, NY 14559.

Ziip Lab Co., Ltd., E District 4F, 5  
Building, Wen Ge Industrial Zone,  
Heshuikou, Gongming St., Guangming  
New District, Shenzhen City,  
Guangdong Province, China 518106.

Ziip Lab S.A., Ave. Golero, 911 Office  
27, Punta del Este—Maldonado,  
Uruguay, 20100.

(c) The Office of Unfair Import  
Investigations, U.S. International Trade  
Commission, 500 E Street SW, Suite  
401, Washington, DC 20436; and

(5) For the investigation so instituted,  
the Chief Administrative Law Judge,  
U.S. International Trade Commission,  
shall designate the presiding  
Administrative Law Judge.

Responses to the complaint and the  
notice of investigation must be  
submitted by the named respondents in  
accordance with section 210.13 of the  
Commission's Rules of Practice and  
Procedure, 19 CFR 210.13. Pursuant to  
19 CFR 201.16(e) and 210.13(a), such  
responses will be considered by the  
Commission if received not later than 20  
days after the date of service by the  
Commission of the complaint and the  
notice of investigation. Extensions of  
time for submitting responses to the  
complaint and the notice of  
investigation will not be granted unless  
good cause therefor is shown.

Failure of a respondent to file a timely  
response to each allegation in the  
complaint and in this notice may be  
deemed to constitute a waiver of the  
right to appear and contest the  
allegations of the complaint and this  
notice, and to authorize the  
administrative law judge and the  
Commission, without further notice to  
the respondent, to find the facts to be as  
alleged in the complaint and this notice  
and to enter an initial determination  
and a final determination containing  
such findings, and may result in the

issuance of an exclusion order or a cease  
and desist order or both directed against  
the respondent.

By order of the Commission.

Issued: December 20, 2018.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2018–28068 Filed 12–26–18; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—DVD Copy Control Association

Notice is hereby given that, on  
December 5, 2018, pursuant to Section  
6(a) of the National Cooperative  
Research and Production Act of 1993,  
15 U.S.C. 4301 *et seq.* (“the Act”), the  
DVD Copy Control Association (“DVD  
CCA”) has filed written notifications  
simultaneously with the Attorney  
General and the Federal Trade  
Commission disclosing changes in its  
membership. The notifications were  
filed for the purpose of extending the  
Act's provisions limiting the recovery of  
antitrust plaintiffs to actual damages  
under specified circumstances.  
Specifically, Shenzhen Soling Industrial  
Co., Ltd., Shenzhen City, Guangdong,  
PEOPLE'S REPUBLIC OF CHINA, has  
been added as a party to this venture.

Also, Fujitsu Limited, Nakahara-ku,  
Kawasaki, JAPAN; and Koninklijke  
Philips Electronics N.V., Eindhoven,  
NETHERLANDS, have withdrawn as  
parties to this venture.

No other changes have been made in  
either the membership or planned  
activity of the group research project.  
Membership in this group research  
project remains open, and DVD CCA  
intends to file additional written  
notifications disclosing all changes in  
membership.

On April 11, 2001, DVD CCA filed its  
original notification pursuant to Section  
6(a) of the Act. The Department of  
Justice published a notice in the **Federal  
Register** pursuant to Section 6(b) of the  
Act on August 3, 2001 (66 FR 40727).

The last notification was filed with  
the Department on August 14, 2018. A  
notice was published in the **Federal  
Register** pursuant to Section 6(b) of the

Act on September 4, 2018 (83 FR  
44903).

**Suzanne Morris,**

*Chief, Premerger and Division Statistics Unit,  
Antitrust Division.*

[FR Doc. 2018–28041 Filed 12–26–18; 8:45 am]

**BILLING CODE 4410–11–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. 2018–48]

#### Stephen R. Kovacs, D.O.; Decision and Order

On August 2, 2018, the Assistant  
Administrator, Diversion Control  
Division, Drug Enforcement  
Administration (hereinafter, DEA or  
Government), issued an Order to Show  
Cause to Stephen R. Kovacs, D.O.  
(hereinafter, Respondent), of Owasso  
and Claremore, Oklahoma. Order to  
Show Cause (hereinafter, OSC), at 1.  
The Show Cause Order proposes the  
revocation of Respondent's Certificates  
of Registration on the ground that he has  
“no state authority to handle controlled  
substances” in Oklahoma, the State in  
which he is registered with the DEA. *Id.*  
(citing 21 U.S.C. 824(a)(3)). It also  
proposes the denial of “any applications  
for renewal or modification of such  
registrations and any applications for  
any other DEA registrations.” OSC, at 1  
(citing 21 U.S.C. 824(a)(3)).

Regarding jurisdiction, the Show  
Cause Order alleges that Respondent  
holds DEA Certificate of Registration  
No. BK9173840 at the registered address  
of 10314 N 138th E Ave., Suite 101,  
Owasso, Oklahoma 74055. OSC, at 2.  
This registration, the OSC alleges,  
authorizes Respondent to dispense  
controlled substances in schedules II  
through V as a practitioner-DW/275. *Id.*  
The Show Cause Order alleges that this  
registration expires on December 31,  
2019. *Id.*

The Show Cause Order further alleges  
that Respondent holds DEA Certificate  
of Registration No. BK7370492 at the  
registered address of 985 West Will  
Rogers Blvd., Claremore, OK 74017,  
with a mailing address of 13616 E 103rd  
St. N, Ste. A, Owasso, Oklahoma 74055.  
*Id.* This registration, the OSC alleges,  
authorizes Respondent to dispense  
controlled substances in schedules II  
through V as a practitioner. *Id.* The  
Show Cause Order alleges that this  
registration expires on December 31,  
2018. *Id.*

The substantive ground for the  
proceeding, as alleged in the Show  
Cause Order, is that Respondent is

“currently without authority to handle controlled substances in the State of Oklahoma, the state in which . . . [he is] registered with DEA.” *Id.* Specifically, the Show Cause Order alleges that, on May 31, 2018, the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control immediately suspended Respondent’s Oklahoma controlled substances registration OBN#29222, and that this registration is associated with Respondent’s practice location at 10314 N 138th E Ave., Suite 101, Owasso, Oklahoma 74055. *Id.* The Show Cause Order further alleges that Respondent’s Oklahoma controlled substances registration OBN#33269, associated with Respondent’s practice location at 985 West Will Rogers Blvd., Claremore, Oklahoma 74017, expired on October 31, 2017 and is listed as “INACTIVE.” *Id.*

The Show Cause Order notifies Respondent of his right to request a hearing on the allegations or to submit a written statement while waiving his right to a hearing, the procedures for electing each option, and the consequences for failing to elect either option. *Id.* at 2–3 (citing 21 CFR 1301.43). The Show Cause Order also notifies Respondent of the opportunity to submit a corrective action plan. OSC, at 3–4 (citing 21 U.S.C. 824(c)(2)(C)).

By letter dated September 7, 2018, Respondent timely requested a hearing.<sup>1</sup> Hearing Request, at 1. According to the Hearing Request, the Oklahoma Bureau of Narcotics & Dangerous Drugs Control (hereinafter, OBNDDC) immediately suspended “for imminent endangerment” Respondent’s State controlled substances registration based on “allegations of professional misconduct.” *Id.* Respondent contests the OBNDDC allegations. *Id.* The Hearing Request admits that Respondent “is currently suspended under the State order from prescribing medications.” *Id.* at 2. It states that, “upon a full and fair hearing of the facts,” Respondent “should not have his State or Federal Certificates of Registration revoked or modified.” *Id.*

The Office of Administrative Law Judges put the matter on the docket and

assigned it to Chief Administrative Law Judge John J. Mulrooney, II (hereinafter, CALJ). On September 10, 2018, the CALJ issued an Order directing the filing of evidence of lack of State authority and a briefing schedule.

The Government filed a timely Summary Disposition Motion “based on Respondent’s lack of state authority to handle controlled substances.” Summary Disposition Motion, at 1. The Government attached to its Summary Disposition Motion a certified copy of the OBNDDC’s letter to Respondent notifying him of his “Immediate Suspension Due to Imminent Danger” dated May 31, 2018. *Id.* at Exh. 4. According to the Summary Disposition Motion, Respondent “is not authorized to possess a DEA registration” in Oklahoma “[a]bsent authority by the State of Oklahoma to dispense controlled substances.” *Id.* at 4. Citing Agency precedent, the Government argues that “even if the period of suspension is temporary or if there is the potential that Respondent’s state controlled substances privileges will be reinstated, summary disposition is warranted.” *Id.*

On September 27, 2018, Respondent timely filed a Response to the Summary Disposition Motion. Attached to the Response is an email from the Deputy General Counsel of the Oklahoma Bureau of Narcotics dated September 13, 2018. The email asks Respondent’s attorney if he “[w]ould . . . be opposed to continuing . . . [Respondent’s] hearing until October 25, 2018.” Response, Exh. 1, at 1. Counsel for Respondent did not object to the continuance. *Id.* at 1. According to the Response, “Respondent’s rights have been severely prejudiced by delaying the state hearing.” *Id.* at 2.

Respondent “admits that the OBNDDC filed the Notice of Immediate Suspension of Respondent’s Oklahoma controlled substances registration on May 31, 2018.” *Id.* at 1. He states, however, that he “has had no opportunity to present evidence or cross-examine witnesses, defenses to which he is absolutely entitled under Oklahoma law” and that “but for” the continuance, he “would have had that opportunity today.” *Id.* at 3. Respondent argues that the Agency precedent on which the Government relies “allowed some form of process with the state . . . before the Government’s motion for summary disposition was granted.” *Id.* at 2. He states that the “state administrative hearing will be concluded in less than one month . . . [at which] time both sides will have a much more complete understanding of the facts, and the ALJ will be able to

more effectively rule on the status of Respondent’s DEA registration.” *Id.* at 3. Respondent asks that the Summary Disposition Motion be denied or, in the alternative, that the deadline for his response be “extended . . . beyond the date of his state administrative hearing.” *Id.*

The CALJ granted the Summary Disposition Motion and recommended that Respondent’s registration be revoked. Order Denying the Respondent’s Request for Extension, Granting the Government’s Motion for Summary Disposition, and Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision of the Administrative Law Judge dated September 28, 2018 (hereinafter, R.D.). The CALJ notes Respondent’s concession that his Oklahoma registration was suspended on May 31, 2018. *Id.* at 3. Citing Agency precedent about stay requests, the CALJ denied Respondent’s request for an extended response deadline. *Id.* After summarizing Agency precedent concerning a registrant’s loss of State authority to dispense controlled substances, the CALJ recommended that Respondent’s registration be revoked and that pending applications for renewal be denied. *Id.* at 4–7.

By letter dated October 18, 2018, the CALJ certified and transmitted the record to me for final Agency action. In that letter, the CALJ advises that neither party filed exceptions.

I issue this Decision and Order based on the entire record before me. 21 CFR 1301.43(e). I make the following findings of fact.

## Findings of Fact

### *Respondent’s DEA Registrations*

Respondent holds two DEA Certificates of Registration. First, Respondent holds DEA Certificate of Registration No. BK9173840, pursuant to which he is authorized to dispense controlled substances in schedules II through V as a practitioner DW/275, at the registered address of 10314 N 138th E Ave., Suite 101, Owasso, Oklahoma 74055. Summary Disposition Motion, Exh. 1 (Certification of Registration Status), at 1. This registration expires on December 31, 2019. *Id.*

Second, Respondent holds DEA Certificate of Registration No. BK7370492, pursuant to which he is authorized to dispense controlled substances in schedules II through V as a practitioner, at the registered address of 985 West Will Rogers Blvd., Claremore, Oklahoma 74017. *Id.* at Exh. 2 (Certification of Registration Status), at

<sup>1</sup> Attached to the Government’s Motion for Summary Disposition is a DEA–12 (Receipt for Cash or Other Items) that, according to the Government’s allegations, Respondent executed when the Government served the OSC on August 8, 2018. Respondent does not challenge the Government’s service-related allegations. The Government does not contest the timeliness of Respondent’s request for a hearing. Government’s Motion for Summary Disposition dated September 19, 2018 (hereinafter “Summary Disposition Motion”), at 2. Thus, I find that Respondent’s Hearing Request was timely since it was filed within 30 days of service of the OSC. 21 CFR 1301.43(a).

1. This registration expires on December 31, 2018. *Id.*

#### *The Status of Respondent's State License*

On May 31, 2018, the OBNDDC immediately suspended due to imminent danger Respondent's "privileges to possess, administer, dispense, prescribe and/or distribute scheduled controlled dangerous substances." *Id.* at Exh. 4, at 1. According to the immediate suspension, the OBNDDC found "by clear and convincing evidence . . . [that Respondent's] continuing status as an Oklahoma Bureau of Narcotics registrant represents an imminent danger to the public health, safety and welfare of the citizens of Oklahoma." *Id.* at Exh. 4, at 3. The OBNDDC's action was based on information that Respondent wrote false Oxycodone (30mg) prescriptions for a patient with the intention of diverting the narcotics back to himself; that Respondent urged a patient to include a false report of stolen Oxycodone on a police report with the intention of getting another refill; that Respondent deleted messages pertaining to his illegal activity from a patient's electronic device; that a patient witnessed Respondent snort Oxycodone between meetings with patients; and that Respondent was opioid dependent. *Id.* at Exh. 4, at 2–3.

Respondent admits that the OBNDDC filed the Notice of Immediate Suspension on May 31, 2018. Response, at 1. There is no evidence in the record that the OBNDDC lifted this Immediate Suspension. Further, according to the online records of the State of Oklahoma, of which I take official notice, I find that this Immediate Suspension is still in effect today and that no Oklahoma controlled substances registration ever assigned to Respondent is currently active.<sup>2</sup> OBNDDC Registration Search Lookup, <https://pay.apps.ok.gov/obnndd/app/search/index.php> (last visited December 11, 2018).

<sup>2</sup> Under the Administrative Procedure Act, an agency "may take official notice of facts at any stage in a proceeding—even in the final decision." United States Department of Justice, Attorney General's Manual on the Administrative Procedure Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint 1979). Pursuant to 5 U.S.C. 556(e), "[w]hen an agency decision rests on official notice of a material fact not appearing in the evidence in the record, a party is entitled, on timely request, to an opportunity to show the contrary." Accordingly, Respondent may dispute my finding by filing a properly supported motion for reconsideration within 15 calendar days of the date of this Order. Any such motion shall be filed with the Office of the Administrator and a copy shall be served on the Government; in the event Respondent files a motion, the Government shall have 15 calendar days to file a response.

Accordingly, I find that Respondent currently is without authority to dispense controlled substances in Oklahoma, the State in which he is registered.

#### **Discussion**

Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized to suspend or revoke a registration issued under section 823 of the Controlled Substances Act (hereinafter, CSA), "upon a finding that the registrant . . . has had his State license or registration suspended . . . [or] revoked . . . by competent State authority and is no longer authorized by State law to engage in the . . . dispensing of controlled substances." With respect to a practitioner, the DEA has long held that the possession of authority to dispense controlled substances under the laws of the State in which a practitioner engages in professional practice is a fundamental condition for obtaining and maintaining a practitioner's registration. *See, e.g., James L. Hooper, M.D.*, 76 FR 71,371 (2011), *pet. for rev. denied*, 481 Fed. Appx. 826 (4th Cir. 2012); *Frederick Marsh Blanton, M.D.*, 43 FR 27,616, 27,617 (1978).

This rule derives from the text of two provisions of the CSA. First, Congress defined the term "practitioner" to mean "a physician . . . or other person licensed, registered, or otherwise permitted, by . . . the jurisdiction in which he practices . . . , to distribute, dispense, . . . [or] administer . . . a controlled substance in the course of professional practice." 21 U.S.C. 802(21). Second, in setting the requirements for obtaining a practitioner's registration, Congress directed that "[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which he practices." 21 U.S.C. 823(f). Because Congress has clearly mandated that a practitioner possess State authority in order to be deemed a practitioner under the CSA, the DEA has held repeatedly that revocation of a practitioner's registration is the appropriate sanction whenever he is no longer authorized to dispense controlled substances under the laws of the State in which he practices. *See, e.g., Hooper, supra*, 76 FR at 71,371–72; *Sheran Arden Yeates, M.D.*, 71 FR 39,130, 39,131 (2006); *Dominick A. Ricci, M.D.*, 58 FR 51,104, 51,105 (1993); *Bobby Watts, M.D.*, 53 FR 11,919, 11,920 (1988), *Blanton, supra*, 43 FR at 27,617.

Under longstanding Agency precedent, DEA revokes the registration of a practitioner who lacks State authority to handle controlled

substances even when the practitioner's State authority was suspended summarily or pending a final decision on the merits. *See, e.g., Bourne Pharmacy, Inc.*, 72 FR 18,273, 18,274 (2007). Similarly, as the CALJ made clear, the facts that a State immediately suspended a respondent's registration and that the respondent may, some day, regain his State registration to dispense controlled substances do not change the salient fact—the respondent is not currently authorized to handle controlled substances in the State in which he is registered.<sup>3</sup> *Mehdi Nikparvarfard, M.D.*, 83 FR 14,503, 14,504 (2018).

Here, Respondent admits that the OBNDDC suspended his Oklahoma controlled substances registration. Further, there is no evidence in the record that Respondent holds any active Oklahoma registration to handle controlled substances. As such, according to Oklahoma law, Respondent currently does not have authority to handle controlled substances in Oklahoma. Okla. Stat. tit. 63, § 2–302 (Westlaw, current with legislation of the Second Regular Session of the 56th Legislature (2018)) (Every person who dispenses any controlled dangerous substance within Oklahoma shall obtain a registration issued by OBNDDC.). Respondent, therefore, is not eligible for a DEA registration. Accordingly, I will order that Respondent's DEA registrations be revoked and that any pending application for the renewal or modification of those registrations be denied. 21 U.S.C. 824(a)(3).

#### **Order**

Pursuant to 28 CFR 0.100(b) and the authority thus vested in me by 21 U.S.C. 824(a), I order that DEA Certificate of Registration Nos. BK9173840 and BK7370492 issued to Stephen R. Kovacs, D.O., be, and they hereby are, revoked. I further order that any pending application of Stephen R. Kovacs, D.O., to renew or modify these registration, as well as any other pending application by him for registration in the State of Oklahoma, be, and it hereby is, denied. This Order is effective immediately.<sup>4</sup>

<sup>3</sup> The CALJ's denial of Respondent's request for an enlargement of time is the correct result. Also, as already discussed, Oklahoma's online records still indicate that Respondent's Oklahoma controlled substances registrations are inactive or inactivated.

<sup>4</sup> For the same reasons the OBNDDC found by clear and convincing evidence that Respondent's continuing status as an Oklahoma Bureau of Narcotics registrant represents an imminent danger to the public health, safety and welfare of the citizens of Oklahoma, I find that the public interest

Dated: December 11, 2018.

**Uttam Dhillon,**

*Acting Administrator.*

[FR Doc. 2018–28072 Filed 12–26–18; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–392]

#### Importer of Controlled Substances Application: Johnson Matthey Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 28, 2019. Such persons may also file a written request for a hearing on the application on or before January 28, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417, (January 25, 2007)

#### SUPPLEMENTARY INFORMATION:

The Attorney General has delegated his authority under the Controlled

Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on October 15, 2018, Johnson Matthey Inc., 2003 Nolte Drive, West Deptford, New Jersey 08066 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Coca Leaves .....	9040	II
Thebaine .....	9333	II
Opium, raw .....	9600	II
Noroxymorphone .....	9668	II
Poppy Straw Concentrate .....	9670	II
Fentanyl .....	9801	II

The company plans to import coca leaves (9040), raw opium (9600), and poppy straw concentrate (9670) in order to bulk manufacture active pharmaceutical ingredients (API) for distribution to its customers. The company plans to also import thebaine (9333), noroxymorphone (9668), and fentanyl (9801) to use as analytical reference standards, both internally and to be sold to their customers to support testing of Johnson Matthey Inc.’s API’s only.

Dated: December 8, 2018.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2018–28073 Filed 12–26–18; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–392]

#### Importer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and been granted registration by the Drug Enforcement Administration (DEA) as an importer of various classes of schedule I or II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as an importer of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for this notice.

Company	FR docket	Published
R & D Systems, Inc.	83 FR 49580.	October 2, 2018.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed company.